Rare Variant of Bartter Syndrome with Sensorineural Deafness

Kumar R1, Kumar P2, Kumar M3

Abstract
Bartter syndrome is an inherited renal tubular disorder characterized by hypokalemia, hypochloremic metabolic alkalosis, hyperreninemia, hyper-prostaglandinism, normal blood pressure, with increased urinary loss of sodium, chloride, potassium, calcium and prostaglandins. There are five known type of Bartter syndrome, out of which type 4 and 5 are very rare. We are presenting here a case of Bartter syndrome with sensorineural hearing loss.

Keywords: Metabolic Alkalosis, Hypokalemia, Bartter Syndrome, Sensorineural Hearing Loss.

Introduction
Bartter syndrome is a rare inherited defect in the thick ascending limb of the loop of Henle 1. It is characterized by hypokalemia, metabolic alkalosis and normal to low blood pressure. Bartter syndrome can be divided into different subtypes on the basis of gene involved viz type 1 - neonatal Bartter’s syndrome, type 2 - neonatal Bartter’s syndrome, type 3 - classic Bartter’s syndrome, type 4 - Bartter’s syndrome with sensorineural deafness, type 5 - Bartter’s syndrome associated with autosomal dominant hypocalcemia 2. A closely associated disorder, Gitelman’s syndrome is a primary renal tubular hypokalemic metabolic alkalosis with hypocalciuria and magnesium deficiency 3 and can be easily distinguished from Bartter’s syndrome on the basis of urinary calcium levels4.

The Case
A 2 years old male was admitted to our hospital with complaints of vomiting, increased thirst and urination for 2 days. Parents also complained about delayed speech and the child was not able to speak even monosyllabous words. No other family member had similar illness and there was no history of parental consanguinity.

On examination, the child was of average built with normal motor milestones but defective language development as only cooing sounds were present. The child was not responding to sound. Blood pressure was 76/60 mm Hg and pulse rate was 136 per minute. Dehydration was present. There was hypothermia but sensorium was normal. Systemic examination was within normal limit.

Laboratory investigations showed serum potassium 1.2 mEq/L (3.5-5 mEq/L), serum sodium-140 mEq/L (136-145 mEq/L), serum chloride- 58mEq/L (96-106 mEq/L), serum bicarbonate 30 mEq/L(24-28), serum magnesium- 1.6 mg/dl (1.8-2.4 mg/dl), serum urea- 18.4 mg/dl, serum creatinine-0.03 mg/ dl, blood pH-7.55 (7.35-7.45). The urine calcium was 8 mmols/24 hour (2.5-7.5 mmols), urine potassium was 186 mmols/24 hour (25-150 mmols), urine chloride 302 mmols/24 hour (110-250 mmols), urine magnesium 10.7 mg/24 hour (1.2-29.2 mg). Urine specific gravity and urine osmolality were normal. Serum aldosteron level was 462.02 ng/l(25-315ng/l).

On audiometric assessment 120db tones of various frequencies were given by head phone which did not elicit any
response including eye blink or head turning suggesting B/L severe to profound hearing loss.

Patient was treated with indomethacin, oral magnesium and potassium supplementation. Patient symptoms improved and discharged and referred to higher center for audiological rehabilitation.

**Discussion**

Bartter’s syndrome is uncommon inherited abnormalities of ion channels in the thick ascending limb of the loop of Henle. It is characterized by hypercalciuria and nephrocalcinosis, and may be associated with maternal polyhydramnios, premature birth and low birth weight, and early onset of symptoms, including vomiting, Polydipsia, dehydration with hypotension, muscle weakness, paresthesias, and developmental delay. We report here a case of two year old boy with Bartter syndrome with bilateral sensorineural deafness. More than hundred cases of Bartter syndrome were identified. To our best knowledge this is the third case of Bartter syndrome with bilateral sensorineural deafness from the Indian community. The infantile BS with sensorineural deafness, or type IV BS, is linked to autosomal recessive mutations in the BSND gene, located on chromosome 1p31 and coding Barttin protein. Barttin protein is an essential subunit of the CIC-Ka and CIC-Kb chloride channels and is expressed in tubular segments spanning from the thick ascending limb to cortical collecting ducts in the kidney, whereas in the inner ear, it is expressed in potassium-secreting epithelial cells. The underlying mechanisms of the salt-losing renal tubular disorder and of the related deafness have been a matter of interest for pediatricians, general practitioners, nephrologists, and otolaryngologists. In regard to hearing loss, the latest studies showed that sensorineural hearing loss in infantile BS is caused by the loss of outer hair cells and by a decrease in the mechano-electrical transduction current of inner hair cells due to a drop in the endocochlear potential.

Fluid and electrolytes should be postnatally replaced according to the extent of the loss. Indomethacin should be started in a low dose (0.2 mg/kg/day). Close monitoring of serum creatinine, urinary prostaglandin, and serum indomethacin levels is mandatory to detect drug toxicity and response to therapy. The dose of indomethacin can then be titrated to achieve an adequate response. The indomethacin therapy has shown to decrease polyuria, renal salt-wasting, hyperprostaglandinuria, hypercalciuria, and nephrocalcinosis.

**Conclusion**

Metabolic syndromes should be suspected in any child presenting with vomiting, polydipsia, polyurea, dehydration and developmental delay. Audiological assessment should be done in all the cases of Bartter syndrome. Early intervention and timely audiological rehabilitation can improve quality of life in such children.

**References**